ALMS
ALMS clinical trials: ALUMIS INC.
Every trial on ClinicalTrials.gov where ALUMIS INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 13
- Trials linked
- 13
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ALMS on the catalyst calendar · ALMS registry changes
- Primary completion Sep 23, 2025ActualPhase 3NCT06588738A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001Alumis Inc · Plaque PsoriasisCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 19, 2025ActualPhase 3NCT06586112A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisAlumis Inc · Plaque PsoriasisCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2027Sponsor estimatePhase 2NCT05739435Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisAlumis Inc · Plaque PsoriasisActive, not recruitingALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 23, 2026ActualPhase 2NCT05966480Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus ErythematosusAlumis Inc · SLEActive, not recruitingALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 24, 2026ActualPhase 1NCT06952634An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver DamageAlumis Inc · Hepatic ImpairmentCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2028Sponsor estimatePhase 3NCT06846541Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisAlumis Inc · Plaque PsoriasisActive, not recruitingALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 18, 2024ActualPhase 1NCT07442149An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005Alumis Inc · Healthy VolunteerCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2024ActualPhase 1NCT07378579An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001Alumis Inc · Healthy VolunteerCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 1, 2025ActualPhase 1NCT06962774An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and Severe Impaired...Alumis Inc · Renal ImpairmentCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 29, 2023ActualPhase 2NCT05600036A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisAlumis Inc · Plaque PsoriasisCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 13, 2024ActualPhase 2NCT05953688POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIUAlumis Inc · Uveitis Posterior Non-InfectiousTerminatedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 1, 2022ActualPhase 1NCT05431634Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy ParticipantsAlumis Inc · Safety and TolerabilityCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2022ActualPhase 1NCT05330858Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsAlumis Inc · PharmacokineticsCompletedALMSLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 13 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner